EUVIMEDEUVIMED entdecken
Crossref

Altered immunophenotypic expression in the peripheral bladder cancer immune landscape

Nathan J Mackenzie, Kate Zimmermann, Clarissa Nicholls, Mahasha Pj Perera, Alexander Ngoo, Penny L Jeffery, Ian Vela, Tony J Kenna, Elizabeth D Williams iD, Patrick B Thomas iD

Immunology & Cell Biology · 2024-11 · 102 (10) · 949-962

DOI: 10.1111/imcb.12829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology & Cell Biology, online erschienen am 30.10.2024. Verfasst von Nathan J Mackenzie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Immunophenotyping. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: PA Research Foundation, Australian Government, Queensland University of Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatments targeting the immune system only benefit a subset of patients with bladder cancer (BC). Biomarkers predictive of BC progression and response to specific therapeutic interventions are required. We evaluated whether peripheral blood immune subsets and expression of clinically relevant immune checkpoint markers are associated with clinicopathologic features of BC. Peripheral blood mononuclear cells isolated from blood collected from 23 patients with BC and 9 age‐matched unaffected‐by‐cancer control donors were assessed using a 21‐parameter flow cytometry panel composed of markers of T, B, natural killer and myeloid populations and immune checkpoint markers. Patients with BC had significantly lower numbers of circulating CD19 + B cells and elevated circulating CD4 + CD8 + T cells compared with the control cohort. Immune checkpoint markers programmed cell death protein 1 (PD‐1) and T‐cell immunoglobulin and mucin‐domain containing‐3 (TIM‐3) were elevated in the total peripheral immune cell population in patients with BC. Within the BC cohort, PD‐1 expression in T and myeloid cells was elevated in muscle‐invasive compared with non–muscle‐invasive disease. In addition, elevated T, B and myeloid PD‐1 cell surface expression was significantly associated with tumor stage, suggesting that measures of peripheral immune cell exhaustion may be a predictor of tumor progression in BC. Finally, positive correlations between expression levels of the various immune checkpoints both overall and within key peripheral blood immune subsets collected from patients with BC were observed, highlighting likely coregulation of peripheral immune checkpoint expression. The peripheral blood immunophenotype in patients with BC is altered compared with cancer‐free individuals. Understanding this dysregulated immune profile will contribute to the identification of diagnostic and prognostic indicators to guide effective immune‐targeted, personalized treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsImmunophenotypingHumansMaleFemaleAgedMiddle AgedBiomarkers, TumorProgrammed Cell Death 1 ReceptorAged, 80 and overLeukocytes, MononuclearTumor Microenvironment

Stichwörter der Autor:innen

Bladder cancerflow cytometryimmunologyperipheral bloodprecision medicine

Substanzen

Biomarkers, TumorProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Queensland University of Technology (QUT), School of Biomedical Sciences at Translational Research Institute (TRI), Brisbane, QLD, Australia.
  • Queensland Bladder Cancer Initiative (QBCI), Brisbane, QLD, Australia.
  • Centre for Immunology and Infection Control, Queensland University of Technology (QUT), Brisbane, QLD, Australia.
  • Centre for Microbiome Research, Queensland University of Technology (QUT), Brisbane, QLD, Australia.
  • Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD, Australia.
  • Australian Prostate Cancer Research Centre - Queensland (APCRC-Q), Brisbane, QLD, Australia.

ORCID-Profile: Elizabeth D Williams, Patrick B Thomas

Förderung

  • PA Research Foundation
  • Australian Government
  • Queensland University of Technology

Zitieren

APA

Mackenzie, N. J., Zimmermann, K., Nicholls, C., Perera, M. P., Ngoo, A., Jeffery, P. L., Vela, I., Kenna, T. J., Williams, E. D., & Thomas, P. B. (2024). Altered immunophenotypic expression in the peripheral bladder cancer immune landscape. Immunology & Cell Biology, 102(10), 949-962. https://doi.org/10.1111/imcb.12829

Vancouver

Mackenzie NJ, Zimmermann K, Nicholls C, Perera MP, Ngoo A, Jeffery PL, et al. Altered immunophenotypic expression in the peripheral bladder cancer immune landscape. Immunology & Cell Biology. 2024;102(10):949-962. doi:10.1111/imcb.12829

BibTeX
@article{Mackenzie2024,
  author = {Mackenzie, Nathan J and Zimmermann, Kate and Nicholls, Clarissa and Perera, Mahasha Pj and Ngoo, Alexander and Jeffery, Penny L and Vela, Ian and Kenna, Tony J and Williams, Elizabeth D and Thomas, Patrick B},
  title = {Altered immunophenotypic expression in the peripheral bladder cancer immune landscape},
  journal = {Immunology & Cell Biology},
  year = {2024},
  volume = {102},
  number = {10},
  pages = {949--962},
  doi = {10.1111/imcb.12829}
}
Kostenlos starten →